Swissmedic approves Novartis’ malaria medicine for babies

Swissmedic has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for babies.

Jul 9, 2025 - 06:00

Swissmedic approves Novartis’ malaria medicine for babies

Swissmedic has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for babies.

Read the original article

Tags:

Previous Article

Pulmonary arterial hypertension market to reach $9.35bn across 7MM by 2034

GSK acquires efimosfermin alfa from Boston Pharma for $2bn

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Biotechnology Equipment Manufacturers, Companies and Suppliers for the Pharmaceutical Industry

Biotechnology Equipment Manufacturers, Companies and Su...

Sep 26, 2024

Risk adjusted net present value: What is the current va...

Dec 15, 2024

Amid backlash, Novo Nordisk reports positive cardiovasc...

Aug 8, 2023